1/2
Drostanolone enanthate
- Min. Order100g/Bag
- Purity99.4%
- Cas No13425-31-5
- Supply Ability1000kg
- Update time2021-11-10
Product Name | Drostanolone enanthate |
CAS No | 13425-31-5 |
EC-No | |
Min. Order | 100g/Bag |
Purity | 99.4% |
Supply Ability | 1000kg |
Release date | 2021/11/10 |
Masteron (Drotaandrosterone propionate)
Description:
Drotaxisterone propionate is an injectable steroid derived from dihydrotestosterone, where modification of the structure of dihydrotestosterone with the 2-methyl group enhances its anabolic function, making drotaxisterone more effective than testosterone in promoting muscle growth. Described in some brochures as a "powerful anabolic steroid and antiestrogen drug," drotaxisterone propionate does have both steroid and antiestrogen properties. However, its anabolic properties are considered moderate, especially when other agents are used. The drug is most commonly used by bodybuilders who are on a diet or by speed-training athletes to increase muscle rigidity, lean muscle mass and strength, lower body fat levels and reduce side effects.
History:
Trotaandrosterone was first introduced in 1959, and Sintek also developed other well-known steroids called Convalesaurus. But trotaandrosterone wasn't available as a prescription drug until about a decade later. Lilly and Cintek reached an agreement in which they split a share of research and development costs in exchange for rights to market research results. So in the United States, Eli Lilly's is sold as Drotaxitron propionate, while the rest of the market is owned by Cintec. Here's a list of licensed products including Drotaxitron in other countries: Sarva-Syntex in Belgium, Cilag in Portugal, Masteril in Britain and Bulgaria, and Metormon in Spain. Trotaandropropionic acid is also popular in many other places under the names Cassenne (France), Mastisol (Shionogi, Japan), and Masterid (Granteau, Germany).
The U.S. Food and Drug Administration has approved drotaxisterone propionate for the treatment of postmenopausal advanced breast cancer in women, which is FDA's clinical guidance for drotaxisterone in the international market. The literature also warns physicians and female patients that the same dose of drotaandrosterone is associated with less masculinization than testosterone propionate. So drotaandrosterone is a safer alternative to testosterone injections. However, 300 mg/week is relatively high. The instructions also warn us that mild masculinity is common, such as voice, worsening acne, facial hair growth and clitoral enlargement. Other studies have reported that masculinity is more pronounced with long-term treatment.
In the 1970s and 1980s, trotaandrosterone enjoyed a high reputation among athletes. But the good times did not last long, manufacturers have begun to stop selling this drug agent. This may be due to the emergence of more effective treatments for breast cancer and a slow decline in the prescription of steroids at this stage. The first to be ready to leave the market was the American drug Drotaxisterone propionate, which was withdrawn from the market around the 1980s. France and Spain have subsequently lost market share. In western countries, trotaandrosterone finally disappeared in the late 1990s. But trontaandrosterone is still sold by Pharmacopias in the United States, where there are no legal restrictions on its market, though its return as a prescription drug seems unlikely.
Specifications provided:
Drotaandrosterone cannot be prescribed as a prescription drug. When manufactured by the manufacturer, it is available in 1ML and 2ML vials and stored in oil in 50mg/ml and 100mg/ml specifications.
Structural features:
Drotaandrosterone is an improved form of dihydrotestosterone. It exhibits different properties through the introduction of methyl groups at carbon-2 (α) and significantly increases the anabolic intensity of steroids by enhancing the antimetabolic activity of 3-hydroxysteroid dehydrogenase in skeletal muscle tissue. Androstanolone propionate is a modified form of flexanol in which the carboxylate ester (propionate) has been attached to the 17-β hydroxyl group. Esterified steroids are less polar than free steroids and are absorbed more slowly from the injection site. Once in the blood, esters are removed to produce free (active) flexols. Esterified steroids are designed to prolong the therapeutic effect after administration and allow less frequent injections than free (unesterified) steroids. The half-life of drotaxisterone propionate is approximately two days after injection.
Side effects (estrogen) :
Drotaxisterone is not aromatized and does not measure estrogenicity. With this steroid, antiandrogen is not necessary because men with a sensitive constitution do not develop male breasts. Since estrogen maintains water retention, drotaandrosterone can make you look leaner without worrying about excessive subcutaneous water retention. So drotaandrosterone is a good hormone of choice for water and fat deposits in the body. As a non-aromatic DHT derivative, drotaxisterone has anti-estrogenic effects and competes with other aromatic substances to bind to aromatase.
Side effects (androgen) :
Although classified as an anabolic steroid, drotaxisterone may still produce androgen side effects, especially when used at higher than normal therapeutic doses. This can include a range of side effects: oily skin, acne, body/facial hair growth. Anabolic/androgen steroids may also aggravate male pattern baldness. Female users should be warned that possible reactions include menstrual irregularities, changes in skin texture, facial hair growth, and clitoral hyperplasia. Drotaxisterone is a steroid that has relatively low androgen activity relative to its tissue-building effects, making it a very high threshold for side effects compared to androgen drugs such as testosterone, methyltestosterone, or flumetestosterone. Note that drotaxisterone is not affected by 5-α reductase, so it is not affected by either finasteride or dutaxisterone used together.
Side effects (hepatotoxicity) :
Drotaxisterone is not C17α -alkylated and has not been shown to be hepatotoxic, so the occurrence of hepatotoxicity is unlikely.
Side effects (cardiovascular) :
Anabolic/androgen steroids may have deleterious effects on serum cholesterol. This includes a tendency to lower HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may convert HDL to LDL balance, leading to a greater risk of atherosclerosis. The relative effect of anabolic/androgenic steroids on serum lipids depends on dose, route of administration (oral versus injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to liver metabolism. Due to its non-aromatic properties, Drostanolone has a stronger negative effect on liver treatment of cholesterol than testosterone or noronone, but a weaker effect than C-17 α alkylated steroids. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and lead to left ventricular hypertrophy, all of which may increase the risk of cardiovascular disease and myocardial infarction.
To help reduce cardiovascular stress, it is recommended to maintain an active cardiovascular exercise program and always minimize intake of saturated fat, cholesterol, and simple carbohydrates during AAS use. Fish oil supplements (4g/day) and natural cholesterol/antioxidant formulations such as Lipid Stabil or products with similar ingredients are also recommended.
Side effects (testosterone inhibition) :
All anabolic/androgen steroids are expected to inhibit endogenous testosterone production when taken at doses sufficient to promote muscle gain. Without the intervention of testosterone stimulants, testosterone levels should return to normal within 1 to 4 months of drug splitting. Note that prolonged myodystrophy hypogonadism may be secondary to steroid abuse and may require medical intervention.
In addition to these side effects, see the steroid side effects section of this book for a more detailed discussion of other potential side effects.
Treatment (Male) :
Drotaxisterone propionate is not approved by the FDA for use in men. Prescription guidelines are not available. The drug is usually injected three times a week for physical or performance enhancement purposes. The total weekly dose is usually 200-400mg, taken for 6-12 weeks. This level of use is sufficient to provide measurable gains in lean muscle mass and strength.
Drotaxisterone propionate is often combined with other steroids to enhance the effect. Common stacks include injectable synthetic metabolites such as Deca-Durabolin (Norone decanoate) or Equipoise (Bodanone), which provide significantly enhanced muscle without excessive water retention. For mass gain, it is usually combined with injections of testosterone. These combinations gain solid muscle and have lower water retention levels and estrogen side effects than these steroids alone (usually at higher doses). However, drotaxisterone propionate is most commonly used during the cutting phase of training. In this case, it is often used in combination with other non-aromatizable steroids such as Winstrol, Primobolan, Parabolan or Anavar and can greatly aid in muscle retention and fat loss.
Treatment (women) :
Guidelines for prescribing drotaxisterone propionate recommend three doses per week of 100mg in total. Treatment should be given for at least 8 to 12 weeks before efficacy assessment. If successful, the drug can continue to be used as long as satisfactory results are obtained. Please note that virus symptoms are common at recommended doses. When used for physical or performance enhancement purposes, dosages of 50 mg per week are most common for 4 to 6 weeks. It is rare to have symptoms of masculinity at doses of 100mg or less per week. Note that due to the short-acting nature of propionate, the total weekly dose is usually subdivided into smaller injections given every one to three days.
Company Profile Introduction